CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Verona Pharma PLC - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Verona Pharma PLC - ADR
Riverside, 3 More London Place
Phone: +44 2032834200p:+44 2032834200 LONDON, SE1 2RE  United Kingdom Ticker: VRNAVRNA
Business Summary
Verona Pharma plc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The Company has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. It has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The Company's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board David R.Ebsworth 70 12/1/2014 12/1/2014
President, Chief Executive Officer, Executive Director David S.Zaccardelli 60 2/1/2020 2/1/2020
Chief Financial Officer Mark W.Hahn 62 2/1/2020 2/1/2020
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Rhinopharma Limited
Verona Pharma Inc.
Verona Pharma, Inc.
VRNA
VRP

General Information
Number of Employees: 209 (As of 12/31/2024)
Outstanding Shares: 681,056,022 (As of 3/31/2025)
Stock Exchange: NASD
Fax Number: +44 2078633314


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 9, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!